Lupin Limited, a leading global pharmaceutical company, has announced the launch of its authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. The medication, Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL, is prescribed for the long-term treatment of patients with urea cycle disorders (UCDs) who cannot be adequately managed through dietary protein restriction or amino acid supplements alone.
Lupin Limited is one of India’s leading multinational pharmaceutical companies, renowned for its strong presence in the global generic and specialty drug markets. Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin has grown from a small vitamin manufacturer into a global healthcare powerhouse with operations spanning more than 100 countries. Headquartered in Mumbai, India, the company is recognized for its commitment to quality, affordability, and innovation in healthcare solutions.
Lupin’s diverse product portfolio includes formulations, biotechnology products, active pharmaceutical ingredients (APIs), and generic medicines across therapeutic areas such as cardiovascular, diabetes, respiratory, central nervous system (CNS), anti-infective, and gastrointestinal treatments. The company also has a growing presence in women’s health and pediatric care. Its branded and generic products cater to millions of patients worldwide, making it a key player in improving global healthcare accessibility.
Research and development (R&D) form the cornerstone of Lupin’s growth strategy. The company invests heavily in developing complex generics, biosimilars, and specialty products, particularly in the United States, Europe, and Japan—three of its largest markets. Lupin operates multiple world-class R&D centers and manufacturing facilities that meet stringent international regulatory standards such as those of the US FDA, UK MHRA, and WHO.
In recent years, Lupin has also focused on expanding its digital and consumer healthcare divisions, emphasizing innovation-driven patient care. Its entry into advanced therapeutic areas like inhalation and biologics underscores its forward-looking approach.
Despite challenges such as regulatory hurdles and price pressures in global markets, Lupin continues to demonstrate resilience through strategic acquisitions, partnerships, and a strong operational foundation. Its dedication to sustainability, ethical practices, and corporate social responsibility further enhances its reputation as a trusted global healthcare company. Today, Lupin Limited stands as a symbol of India’s pharmaceutical excellence—combining innovation, integrity, and impact to deliver better health for a better world.
